about
Use of ciprofloxacin during breastfeedingDrug use and/or exposure in pregnancy: Presence of risk versus quantity of risk.Pregnancy outcomes following first-trimester exposure to topical retinoids: a systematic review and meta-analysis.Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis.Fluconazole exposure during pregnancy.Fluconazole use during breastfeeding.Folic acid, body mass index and cardiovascular malformations.Pregnancy outcome after varenicline exposure in the first trimester.Exposure to fluconazole and risk of congenital malformations in the offspring: A systematic review and meta-analysis.Maternal SSRI discontinuation, use, psychiatric disorder and the risk of autism in children: a meta-analysis of cohort studies.Prenatal selective serotonin reuptake inhibitor use and the risk of autism spectrum disorder in children: A systematic review and meta-analysis.Comment on "Identifying Human Teratogens: An Update".Pregnancy outcome following maternal exposure to mirtazapine: a multicenter, prospective study.Effect of subacute methyl parathion administration on the pharmacokinetics and pharmacodynamics of nifedipine in rats.Protective effect of an adenosine A1 receptor agonist against metamidophos-induced toxicity and brain oxidative stress.Defining a medication class as a teratogen: may the evidence be with you and not the FDA Pregnancy Risk Categories.Effect of glucagon on amitriptyline-induced cardiovascular toxicity in rats.Valproate prescribing trends for non-epilepsy indications in women of reproductive age warrants effective measures and increased surveillance.Comment on: "Indigenous Medicine Use for Sex Selection During Pregnancy and Risk of Congenital Malformations: A Population-Based Case-Control Study in Haryana, India".Pregnancy outcomes in women on metformin for diabetes or other indications among those seeking teratology information services.False-positive amphetamine/ecstasy (MDMA/3,4-methylenedioxymethamphetamine) (CEDIA) and ecstasy (MDMA/3,4-methylenedioxymethamphetamine) (DRI) test results with fenofibrate.Comment on "Use of antibiotics during pregnancy and the risk of major congenital malformations: a population based cohort study" by Muanda et al.Comment on the case report "Limb deformity in a newborn. Is rifampicin just an innocent bystander?" by Kalayci et al.Response to "Congenital microtia in a neonate suspected of isotretinoin exposure one month before pregnancy: A case report"Dose-Dependent Risk of Malformations With Antiepileptic Drugs: An Analysis of Data From the EURAP Epilepsy and Pregnancy RegistryIn utero exposure to methotrexate and risk of congenital malformationsPregnancy outcomes after maternal betahistine exposure: A case seriesThe role of smoking in the development and progression of structural damage in axial SpA patients: A systematic review and meta-analysisPregnancy outcomes following quinolone and fluoroquinolone exposure during pregnancy: A systematic review and meta-analysisUse of ondansetron during pregnancy and the risk of major congenital malformations: A systematic review and meta-analysisComment on "Evaluation of Potential Drug-Drug Interactions in Adults in the Intensive Care Unit: A Systematic Review and Meta-analysis"Prenatal Antidepressant Use and Risk of Autism Spectrum Disorders in Children
P50
Q28083890-257AA88C-0A7F-498B-BDA9-B732960DAE67Q35686948-88679965-DD9A-4990-A45B-FB028A1DF94EQ35717381-85FA80AF-560A-4BC1-86E0-500517726874Q35877606-5C5F37A9-C3B2-40B5-9EFD-2C945A21E309Q35970281-B3F56CB8-494A-4B31-9920-A5374BFFFF18Q36166283-521DDA73-B237-4C6F-A716-174F3A636C68Q36791295-AF229D48-7D52-4203-9344-6673B90FCF96Q37594753-FF4CCF58-0206-4904-8F9A-11D07126352EQ38365918-5BD02B5C-EC4D-4C74-B4A4-2F3A18F1D0F4Q38653394-A18037B9-8640-46BC-AA10-810B89FB9A6BQ38964187-E6A9748D-B24C-4F0B-983D-05EE23CEBD1DQ41126612-F9CF4992-C08E-4DA1-A9C8-4CB113C22FB7Q41129361-2ADD3C44-9B95-42D9-8F2B-DE023E49D261Q42729583-356BC5A1-72B3-4D41-8DBF-0511C09D9155Q43271960-A79473CC-692D-49C0-83B6-32FABCF07DBAQ44252822-C8E393B7-36FB-4C57-B915-CECF3BD7C6B0Q46442346-88524308-BE98-4DFA-83C1-FC0E63D3A17FQ46610867-E5305FA7-F0E8-4897-AA91-A175849F7091Q47367856-0CE4A4F2-F9A1-40BF-9736-20DA0493B39DQ47583728-3F36AEA6-3F46-492F-A594-001D130EF5D1Q48223077-68AFA461-54D1-4B86-84BC-F0595D252940Q48282561-2AA9325D-65CE-4252-9923-0869FC982318Q54676663-88D97318-802A-4F67-9040-0ADE197F1303Q86003635-3501AC8D-8CA9-4DD3-AD4C-8B811212BA7AQ86177136-7C700E66-4243-4FD5-A5F7-2E86D6A2C895Q87247693-46AD7987-6DA5-4D71-A76C-B7FCFD497AF3Q89123144-CEBEA5A2-532F-41ED-AFF8-3D511192B579Q90968188-4ED41806-9A6C-4A75-B9A3-2E0E2A729F91Q91437092-5068DE52-047F-4EFB-80CF-299F25D8B6AAQ92230206-42E27D53-A587-4A12-820C-AD522899A9B5Q93043934-6E374C1F-B330-4090-9545-8CE2C9F28F02Q95388364-F4E64D6B-A8D1-41E1-95C9-01C64093A2A2
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Yusuf C Kaplan
@ast
Yusuf C Kaplan
@en
Yusuf C Kaplan
@es
Yusuf C Kaplan
@nl
type
label
Yusuf C Kaplan
@ast
Yusuf C Kaplan
@en
Yusuf C Kaplan
@es
Yusuf C Kaplan
@nl
prefLabel
Yusuf C Kaplan
@ast
Yusuf C Kaplan
@en
Yusuf C Kaplan
@es
Yusuf C Kaplan
@nl
P106
P31
P496
0000-0003-0369-7934